Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 04/05/2026

    How personalised is healthcare?

    This year’s Health Congress at Furtwangen University (HFU) focused on the timely topic of personalised healthcare. With the theme “Health for EVERYONE! – Successful Strategies Through personalised Healthcare,” HFU hosted the event for the 15th time in collaboration with the Black Forest-Baar Health Network, the Furtwangen University Support Association PRO HFU e.V., and the City of Furtwangen.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-personalised-healthcare
  • Press release - 28/04/2026

    Breast cancer brain metastases: patterns in immune cells could improve therapy decisions

    Brain metastases are among the most serious complications of breast cancer. Researchers at Heidelberg University, DKFZ, and UKHD have concluded an investigation of the immune cells in the brain tissue surrounding these breast cancer brain metastases. Their findings: spatial distribution patterns of immune cells are associated with prolonged patient survival. These findings could help to guide use of immunotherapies for breast cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/breast-cancer-brain-metastases-patterns-immune-cells-could-improve-therapy-decisions
  • Press release - 24/04/2026

    New Medical Director of the Department of Nephrology

    Prof. Dr. Halbritter has served as the new Medical Director of the Department of Nephrology at the Medical Center – University of Freiburg since April 2026. With his expertise, he is enhancing care for patients with kidney disease: The goal is to prevent kidney failure through early diagnosis and the implementation of strategies to slow disease progression. For cases where kidney failure has already occurred, the focus is on organ replacement.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-medical-director-department-nephrology
  • Press release - 15/04/2026

    Pacemakers for the Brain

    Brain-computer interfaces can read neural signals and influence brain activity. We spoke with Pascal Fries about how this technology can benefit people with neurological and psychiatric conditions, future developments, and his views on ethical boundaries.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pacemakers-brain
  • Press release - 14/04/2026

    T-helper cells switch to self-protection mode under prolonged stress

    Chronic infections cause long-term changes in key immune cells. T helper cells suppress their immune function to ensure their survival. New targets for vaccines and cancer immunotherapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/t-helper-cells-switch-self-protection-mode-under-prolonged-stress-1
  • Press release - 10/04/2026

    New study identifies clinically relevant changes in airway wall thickness in COPD and at-risk individuals

    A recent study published in the European Respiratory Journal provides important new insights into the early identification and monitoring of chronic obstructive pulmonary disease (COPD). The focus is on airway wall thickness as an imaging marker for structural remodeling processes in the lungs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-study-identifies-clinically-relevant-changes-airway-wall-thickness-copd-and-risk-individuals
  • Press release - 10/04/2026

    Molecular analyses could improve treatment options for a rare soft tissue tumor

    Desmoplastic small- and round-cell tumor is rare, aggressive, and difficult to treat. Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have comprehensively analyzed 30 tumors and identified potential personalized treatment options for nearly all patients. In some patients, new targeted approaches were able to halt the disease for a surprisingly long time.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-analyses-could-improve-treatment-options-rare-soft-tissue-tumor
  • Photoimmunotherapy - 09/04/2026 Zu sehen ist in einer Fluoreszenz-Aufnahme unter dem Mikroskop runde Ansammlungen in blauer Farbe, die die Zellkerne darstellen und rote Signale dicht daneben, die die Konjugate darstellen, all´ das vor schwarzem Hintergrund.

    Switching off tumours with light: how photons can be used to target prostate cancer

    Prostate cancer is the most common cancer among men in Germany. Relapses and the harsh side effects of traditional treatments remain a major challenge, even with advanced surgical techniques. At the University of Freiburg, Dr. Wolf is pioneering the development of photoimmunotherapy. Photoimmunotherapy combines light, antibodies and a specialised dye to precisely target tumour cells - simultaneously 'waking up' the immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/news/switching-tumours-light-how-photons-can-be-used-target-prostate-cancer
  • Press release - 09/04/2026

    “Positions, please!”

    For over a decade, a class of drugs called BET inhibitors has been tested in cancer trials with high expectations. The biology looked promising. Many cancers depend on oncogenes that (BET) proteins help activate, so blocking BET proteins should slow tumor growth. In the lab, it often did. In patients, results were mostly disappointing: limited responses, significant side effects, and no clear way to predict which tumors would respond at all.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/positions-please
  • Press release - 07/04/2026

    No soft drink before the massage

    How does sugar affect relaxation exercises? A new study carried out by researchers from the University of Konstanz provides revealing insights into the connection between blood glucose and the autonomic nervous system: The intake of sugar counteracts relaxation.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/no-soft-drink-massage
  • Press release - 02/04/2026

    Pocket-sized biomedical technology to become smarter Volkswagen Foundation supports mobile health expert Professor Walter Karlen

    The Volkswagen Foundation is supporting the Ulm scientist Professor Walter Karlen with more than 940,000 euros from the funding initiative "Momentum - funding for first-time researchers". The engineer has headed the Institute of Biomedical Engineering at Ulm University since 2021. Karlen conducts research in the field of mobile health on so-called Medicine Wearables, i.e. portable technology for recording health data.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/pocket-sized-biomedical-technology-become-smarter-volkswagen-foundation-supports-mobile-health-expert-professor-walter-karlen
  • Press release - 01/04/2026

    Digital Assistance System Designed to Prevent Recurrent Heart Disease

    Women who have experienced a stroke or heart attack are at a higher risk of mortality than men. Fraunhofer researchers want to improve gender-specific aftercare with a customized assistance system – thus helping to prevent further heart disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/digital-assistance-system-designed-prevent-recurrent-heart-disease
  • Press release - 31/03/2026

    First steps towards cell therapy for brain disorders

    Researchers in Freiburg have found a way to selectively replace defective immune cells in the blood vessels of the brain using an animal model. This is an important first step towards cell therapies for Alzheimer’s disease and other brain disorders. The findings were recently published in the journal Nature Immunology.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/first-steps-towards-cell-therapy-brain-disorders
  • Proof-of-concept study of organoid technology - 26/03/2026 Smiling man with glasses wearing a white lab coat.

    Can organoids improve the treatment of pancreatic cancer?

    A clinical trial called UNITEPANC is exploring whether organoid-based approaches can improve the treatment of pancreatic cancer. BIOPRO Baden-Württemberg spoke with the study’s principal investigator and pancreatic cancer specialist, Prof. Dr. Thomas Seufferlein of University Hospital Ulm, to discuss the disease more broadly along with the specific aims of the trial. The interview was conducted by Walter Pytlik on behalf of BIOPRO.

    https://www.gesundheitsindustrie-bw.de/en/article/news/can-organoids-improve-treatment-pancreatic-cancer
  • Press release - 25/03/2026

    The Influence of Lymph Node Architecture on Lymphoma

    For the first time, researchers have succeeded in mapping the organization of immune cells in human lymph nodes. The study was led by scientists from Heinrich Heine University Düsseldorf, Düsseldorf University Hospital, the DKFZ, the European Molecular Biology Laboratory (EMBL), and the Max Delbrück Center (MDC) in Berlin. They were able to demonstrate why the architecture of healthy lymph nodes is altered in malignant lymphomas.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/influence-lymph-node-architecture-lymphoma
  • Press release - 24/03/2026

    Ovarian Cancer: Adipose Tissue Influences the Efficacy of Immunotherapy

    In ovarian cancer, immunotherapies using checkpoint inhibitors have so far been effective in only a small number of patients. Researchers at the HI-TRON Mainz* have now discovered that lipid metabolism processes in the tumor microenvironment play a decisive role in how well such therapies work. The findings open up new avenues for using immunotherapies in a more targeted manner, increasing their effectiveness, and overcoming resistance.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eierstockkrebs-fettgewebe-beeinflusst-wirksamkeit-der-immuntherapie
  • Press release - 23/03/2026

    After a Heart Attack: Inflammation Weakens the Heart’s Energy Production

    Why does heart function often continue to deteriorate after a heart attack, even though blood flow has been restored? A research team from the DZHK sites Heidelberg and North has now identified an important mechanism: an inflammatory switch in cardiomyocytes can impair cellular energy production and thereby drive the development of heart failure. The results were published in Nature Communications.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/after-heart-attack-inflammation-weakens-hearts-energy-production
  • Press release - 19/03/2026

    New Approaches for Treatment-Resistant Disorders

    The German Center for Mental Health (DZPG) conducts nationwide research on individualized treatments for depression, anxiety disorders, and addiction. Its approach combines established therapeutic methods with innovative strategies to enhance overall treatment efficacy. The primary beneficiaries are patients for whom conventional therapies have so far proven insufficiently effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-approaches-treatment-resistant-disorders
  • Press release - 19/03/2026

    Carl-Zeiss-Stiftung Funds Pioneering AI Project at the DKFZ

    How can artificial intelligence support medical imaging diagnostics in the future and significantly improve patient care? Researchers led by Lena Maier-Hein (German Cancer Research Center, DKFZ, and NCT Heidelberg) have developed an innovative concept to address this question. The Carl Zeiss-Stiftung is funding the MEDAL* project with a total of three million euros.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/carl-zeiss-stiftung-funds-pioneering-ai-project-dkfz
  • Press release - 19/03/2026

    How old are we really?

    Ageing is a highly individual process. An international consortium coordinated by researchers in Konstanz has developed a method that uses biomarkers to determine a person's biological age – a valuable tool for research on ageing and the development of new approaches in preventive medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-old-are-we-really
  • Press release - 19/03/2026

    Psilocybin combined with psychotherapy shows significant efficacy in treatment-resistant depression

    The results of the EPIsoDE study show that psilocybin can have a significant antidepressant effect. It is important that its use be integrated into psychotherapeutic pre- and post-treatment care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/psilocybin-combined-psychotherapy-shows-significant-efficacy-treatment-resistant-depression
  • Press release - 17/03/2026

    Targeting Cancer Drugs More Effectively: First EU Project Integrates Pharmacogenomics into Tumor Boards

    The Dr. Margarete Fischer-Bosch Institute for Clinical Pharmacology (IKP) at the Bosch Health Campus in Stuttgart is leading Europe’s first EU project to systematically integrate pharmacogenomics into molecular tumor boards (MTB). The goal of PGxMTB is to systematically incorporate patients’ genetic factors into treatment decisions, thereby making cancer therapies safer and more effective.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/targeting-cancer-drugs-more-effectively-first-eu-project-integrates-pharmacogenomics-tumor-boards
  • Press release - 12/03/2026

    Brain Diseases: Certain Neurons Are Especially Susceptible to ALS and FTD

    Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) belong to a spectrum of neurodegenerative diseases with overlapping symptoms. Many patients have a common hallmark: A protein called TDP-43 clumps together in the neurons of the brain to form tiny lumps. Researchers at DZNE and Ulm University Hospital, together with international experts, have now discovered that these pathological changes primarily affect certain cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-diseases-certain-neurons-are-especially-susceptible-als-and-ftd
  • Press release - 10/03/2026

    Advanced melanoma: Antibodies in the blood indicate side effects of immunotherapy

    Immunotherapies have greatly improved the treatment of metastatic melanoma, but they can cause serious side effects. A study led by researchers from Heidelberg University's Medical Faculty, the Heidelberg University Hospital, and the NCT in Heidelberg now shows that autoantibodies detected in the blood before the start of therapy could help to better assess the individual risk of side effects in patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/advanced-melanoma-antibodies-blood-indicate-side-effects-immunotherapy
  • Press release - 09/03/2026

    Early detection contributes to declining breast cancer mortality rates in Europe

    The introduction of mammography screening programs in Europe has significantly changed breast cancer diagnoses, accompanied by a decline in breast cancer mortality rates. This is shown by the most comprehensive analyses of population-based data on breast cancer in 21 European countries to date, led by the DKFZ. The most striking finding: after the introduction of screening, significantly more early-stage, less advanced tumors were detected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/early-detection-contributes-declining-breast-cancer-mortality-rates-europe
  • Press release - 02/03/2026

    Novel therapy for Phelan-McDermid syndrome Drug development to be funded with up to 1.7 million euros

    An international team led by Professor Tobias M. Böckers from Ulm University Medical Centre has been awarded up to 1.7 million euros to develop a novel therapy for a rare, syndromic form of autism. The research project focuses on a gene whose loss of function can manifest itself in severe impairments in language, behaviour and everyday functions of those affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/novel-therapy-phelan-mcdermid-syndrome-drug-development-be-funded-17-million-euros
  • Event - 12/03/2026 - 11/06/2026

    Virus-based Therapies Seminar Series

    Biberach and Online, Seminar
    https://www.gesundheitsindustrie-bw.de/en/event/virus-based-therapies-seminar-series
  • Press release - 18/02/2026

    New centre for cell research

    Technology impulse for the Lake Constance region: The new Single Cell Centre at the University of Konstanz offers technology and expertise to study cells individually and at high resolution – for applications in medical diagnostics, medication development and basic research at universities.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-centre-cell-research
  • Press release - 18/02/2026

    3D microtumors could revolutionize treatment decisions

    Chemotherapy is often a central component of treatment for advanced colorectal cancer. However, not every therapy is equally effective for every patient. Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* stem cell institute, and the biotech company Xilis in Utrecht, Netherlands, have now developed a new method for selecting the most effective drug before treatment begins.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-microtumors-could-revolutionize-treatment-decisions
  • Press release - 17/02/2026

    Tracing Tumors in Cerebrospinal Fluid: A New Opportunity for Precision Diagnostics in Brain Tumors

    In a published scientific study, researchers have succeeded in accurately diagnosing common types of brain tumors in children and adolescents based on tumor-derived genetic material in cerebrospinal fluid. Until now, these so-called liquid biopsies were not capable enough for such reliable diagnostics. The international research team has therefore optimized a sequencing technique and developed an AI-based computational method. In a later step,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/tracing-tumors-cerebrospinal-fluid-new-opportunity-precision-diagnostics-brain-tumors
  • Press release - 13/02/2026

    Molecular cause of radiation damage identified

    A severe side effect of radiation therapy can be debilitating fibrotic skin damage. Scientists at the German Cancer Research Center (DKFZ) have now identified a key factor in the development of this radiation damage. Modulating this factor could potentially prevent this severe adverse effect.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-cause-radiation-damage-identified
  • Press release - 13/02/2026

    How pancreatic cancer prepares tumour environment Possible biomarker for earliest stage of development

    Even before a tumour in the pancreas becomes discernible, an activated cancer gene actively remodels its future environment and creates an inflammatory and immune-defensive microenvironment in which the carcinoma can grow. The scientists' study opens up new possibilities for developing personalised intervention strategies - before a difficult-to-treat tumour even develops.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-pancreatic-cancer-prepares-tumour-environment-possible-biomarker-earliest-stage-development
  • Press release - 04/02/2026

    A double-edged sword: Chronic cellular stress promotes liver cancer - but at the same time renders tumors vulnerable to immunotherapy

    A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response to the tumor. This has now been published in the journal Nature by a team led by researchers from the DKFZ, the UKT, and the Sanford Burnham Prebys Medical Discovery Institute. However, the results also show that this very mechanism could help identify patients who respond particularly well to immunotherapy in the…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/double-edged-sword-chronic-cellular-stress-promotes-liver-cancer-same-time-renders-tumors-vulnerable-immunotherapy
  • Rewriting the transcript to heal diseases - 29/01/2026 A colourful mRNA to which an arginyl tRNA docks. Both nucleic acid sequences are modified at one point.

    Therapy involving the umlauts of the genetic alphabet

    tRNAs are essential components of the protein synthesis machinery that also act as molecular switches in gene regulation and consequently in disease processes such as cancer. The Heidelberg-based start-up Umlaut.bio is developing novel therapeutics that specifically target tRNAs to intervene at the molecular origin of disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/therapy-involving-umlauts-genetic-alphabet
  • Press release - 22/01/2026

    Knowledge Connector: better clinical decisions in molecular precision oncology

    Researchers at the National Center for Tumor Diseases (NCT) Heidelberg and the German Cancer Research Center (DKFZ) have developed a digital tool that significantly accelerates and improves clinical decisions in molecular precision oncology. The Knowledge Connector enables the structured and standardized evaluation of very extensive molecular tumor profiles and makes them available for personalized therapy decisions faster than before.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/knowledge-connector-better-clinical-decisions-molecular-precision-oncology
  • Press release - 17/12/2025

    Improving cancer therapy with artificial organs DFG funds research training group "Org-BOOST" with around nine million euros

    Recreating tumour tissue in the laboratory as realistically as possible and developing new approaches for personalised cancer medicine: A total of 20 doctoral students in the life sciences and ten Medicine students will be researching this in the new "Organoid-Based mOdelling of Solid Tumours" research training group. They want to gain a better understanding of cancer and better predict the course of the disease and the effect of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/improving-cancer-therapy-artificial-organs-dfg-funds-research-training-group-org-boost-around-nine-million-euros
  • Press release - 17/12/2025

    mRNA rejuvenates aging immune system - the liver as a fountain of youth

    Can the weakened immune systems of older individuals be rejuvenated? Researchers from the DKFZ, HI-STEM*, and the Broad Institute have demonstrated that this is possible with an innovative approach. In a study, the team showed that mRNA technology can be used to transform the liver in mice into a temporary source of important immune regulatory factors that are naturally lost during aging.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mrna-rejuvenates-aging-immune-system-liver-fountain-youth
  • Press release - 16/12/2025

    New measures to make EU health sector more innovative, competitive and resilient

    The European Commission has today proposed an ambitious package of measures to improve the health of EU citizens, while ensuring the long-term resilience and competitiveness of the health sector.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-measures-make-eu-health-sector-more-innovative-competitive-and-resilient
  • Press release - 08/12/2025

    New mutation catalog facilitates personalized cancer therapy

    When gene mutations are found in the tumor of cancer patients, it is often unclear whether they promote tumor growth or whether a targeted therapy could be effective. A research team led by the Medical Center - University of Freiburg has now compiled a catalog in which over 11,000 gene variants of a central gene family were examined and evaluated for their role in tumor growth.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-mutation-catalog-facilitates-personalized-cancer-therapy
  • Press release - 25/11/2025

    CELLnROLL receives funding from EXIST Research Transfer

    CELLnROLL is a spin-off from the Max Planck Institute for Intelligent Systems. The newly founded company develops a high-precision microrobotic-based cell sorting system to help clinicians make fast, affordable, and informed decisions for cancer diagnostics. Now, the project has received €865,000 in funding through the EXIST Transfer of Research program, a funding program initiated by the German Federal Ministry for Economic Affairs and Energy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cellnroll-receives-funding-exist-research-transfer
  • Press release - 24/11/2025

    Shield against metastases and genetically protected CAR-T cells: Double honor for Mirco Julian Friedrich

    Physician and cancer researcher Mirco Julian Friedrich from the German Cancer Research Center (DKFZ), the stem cell research institute HI-STEM*, and Heidelberg University Hospital (UKHD) has received two awards for two independent research projects: his novel approach to preventing liver metastases and his research on T cells, which he modifies to better protect them from attacks by natural killer cells.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/shield-against-metastases-and-genetically-protected-car-t-cells-double-honor-mirco-julian-friedrich
  • Press release - 17/11/2025

    How painkillers can contribute to anemia in cancer patients

    Researchers from the German Cancer Research Center and the University of Freiburg show how certain painkillers influence the iron metabolism of liver cancer cells and can thus contribute to iron deficiency and anemia in cancer patients.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-painkillers-can-contribute-anemia-cancer-patients
  • Press release - 07/11/2025

    Overcoming Tumor Resistance to Immunotherapy: The European Research Council awards international project led by Heidelberg Medical Faculty

    In the PRECISION-ImmunoRad project, a multidisciplinary team of scientists from Heidelberg, USA, and Cyprus will unite their expertise to develop novel curative therapeutic strategies for currently hard-to-treat cancers. These strategies will integrate high-precision ion beam therapy with genetically engineered immune cells therapies (CAR-T cells), personalized cancer vaccines, and the targeted reprogramming of the tumor immune microenvironment.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/overcoming-tumor-resistance-immunotherapy-european-research-council-awards-international-project-led-heidelberg-medical-faculty
  • Artificial intelligence: opportunities for healthcare - 06/11/2025 Graphic showing various options for integrating GenAI into a company. These are via SiaS tokens, in a private cloud and with proprietary hardware. They are compared in terms of initial costs, running costs, data security and dependency.

    More than just deskwork: opportunities and obstacles for generative AI in healthcare

    Generative artificial intelligence (GenAI) has enormous potential in healthcare, ranging from automating time-consuming deskwork to supporting diagnoses. It is not just for the big players; there are also cost-effective ways for smaller companies and institutions to utilize GenAI.

    https://www.gesundheitsindustrie-bw.de/en/article/news/more-just-deskwork-opportunities-and-obstacles-generative-ai-healthcare
  • Press release - 04/11/2025

    Brain Tumor Charity supports immunotherapy for childhood brain tumors with 1.5 million pounds sterling

    Ependymomas, brain tumors that occur particularly in young children, are especially difficult to treat and more than half of the children affected have an increased risk of relapse. As part of an international consortium, the KiTZ, the DKFZ, the MFHD and UKHD have received a grant of 1.5 million pounds sterling (GBP) from the British organization The Brain Tumor Charity to develop a new type of immunotherapy for ependymoma.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/brain-tumor-charity-supports-immunotherapy-childhood-brain-tumors-15-million-pounds-sterling
  • Press release - 29/10/2025

    Replacing, reducing and refining animal testing Official launch of integrative 3R Centre at Ulm University

    Developing replacement methods for animal testing is the main goal of the 3R network. One of three new 3R centres in Baden-Württemberg was launched at Ulm University at the beginning of the year and has now officially started work with a kick-off event. The abbreviation 3R stands for "Replace, Reduce, Refine", i.e. replace and reduce animal testing and improve the conditions for unavoidable animal experiments.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/replacing-reducing-and-refining-animal-testing-official-launch-integrative-3r-centre-ulm-university
  • Press release - 28/10/2025

    AI solutions from the DKFZ set new standards in medical image processing

    Researchers at the German Cancer Research Center (DKFZ) have achieved outstanding success at this year's world-leading forum for medical image processing and computer-assisted intervention. Two DKFZ departments competed in eight international AI competitions – and won seven of them. The successes cover key areas of oncology – from early detection and diagnosis to therapy support and follow-up care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ai-solutions-dkfz-set-new-standards-medical-image-processing
  • Press release - 27/10/2025

    OnkoAktiv receives Cancer Innovation Award 2025

    The nationwide OnkoAktiv network, founded at the National Center for Tumor Diseases (NCT) in Heidelberg, has been awarded the Baden-Württemberg Cancer Innovation Prize 2025. The prize recognizes OnkoAktiv for its pioneering role and groundbreaking contribution to the integration of exercise into oncological care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/onkoaktiv-receives-cancer-innovation-award-2025
  • Press release - 16/10/2025

    Sleep as the key to understanding ME/CFS

    The Federal Ministry of Research, Technology and Space (BMFTR) is supporting the “Sleep-Neuro-Path” research network with around 1.6 million euros. Coordinated by the Central Institute of Mental Health (CIMH) in Mannheim, a team of scientists is investigating the role of sleep-related biomarkers in the development of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/sleep-key-understanding-mecfs
  • Press release - 15/10/2025

    NGS-based diagnostics for identifying sepsis pathogens wins EARTO Innovation Award

    A method developed at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB enables bacterial, viral, fungal, or parasitic pathogens in sepsis patients to be identified much faster than before and with the highest precision. The approach is based on high-throughput sequencing of cell-free DNA circulating in the blood and was honored with the EARTO Innovation Award in the "Impact Delivered" category on October 14,…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/ngs-based-diagnostics-identifying-sepsis-pathogens-wins-earto-innovation-award
  • Press release - 10/10/2025

    Acidic tumor environment promotes survival and growth of cancer cells

    Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells. A research team from the DKFZ and the IMP in Vienna has now discovered that the acidic pH value in tumor tissue is a decisive factor in how pancreatic cancer cells adapt their energy metabolism in order to survive under these adverse conditions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/acidic-tumor-environment-promotes-survival-and-growth-cancer-cells
  • Press release - 09/10/2025

    Another step towards a cure Vitamin A transporter reactivates latent HIV

    Human immunodeficiency viruses (HIV) are insidious. They can evade the immune defence and antiviral drugs by becoming "latent". In this state, they are largely invisible and unassailable. As long as these dormant viruses persist, there is no cure for HIV/AIDS. However, researchers at Ulm University Hospital have discovered a new way to reactivate latent HI viruses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/another-step-towards-cure-vitamin-transporter-reactivates-latent-hiv
  • Press release - 06/10/2025

    3D imaging points to possible cause of sudden cardiac death

    An imaging technique developed by Freiburg researchers provides insights into cardiac arrhythmias that can cause sudden cardiac death in animal models. The changes discovered could explain why even seemingly healthy people are sometimes affected.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/3d-imaging-points-possible-cause-sudden-cardiac-death
  • Press release - 29/09/2025

    Actin scaffold in cell nucleus explains survival of cancer cells

    Researchers from the Cluster of Excellence CIBSS have demonstrated that an actin scaffold stabilizes the cell nucleus upon mechanical stress. This protective mechanism helps cancer cells to avoid dying during their migration in the body. In the long term, targeted interventions in this mechanism could help to prevent metastases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/actin-scaffold-cell-nucleus-explains-survival-cancer-cells
  • Press release - 23/09/2025

    Mutation in non-coding DNA worsens leukaemia prognosis Ulm study uncovers previously unknown disease-promoting mechanism

    Why is blood cancer particularly aggressive in some patients? Researchers at Ulm University Hospital have characterised a mutation in the so-called NOTCH1 gene that significantly influences the prognosis of chronic lymphocytic leukaemia (CLL). Remarkably, this mutation is located in the non-coding region of the gene – an area of DNA long considered less relevant for disease mechanisms.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mutation-non-coding-dna-worsens-leukaemia-prognosis-ulm-study-uncovers-previously-unknown-disease-promoting-mechanism
  • Press release - 23/09/2025

    Not all ALK fusions act the same: Variants influence treatment success in lung cancer

    About five percent of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way. However, new research led by scientists from the German Cancer Research Center (DKFZ) and Stanford University shows that not all fusion variants behave alike.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/not-all-alk-fusions-act-same-variants-influence-treatment-success-lung-cancer
  • Press release - 16/09/2025

    New CRISPR method leads to a better understanding of cell functions

    The 2020 Nobel Prize in Chemistry was awarded for the development of CRISPR/Cas9, a method also known as “gene scissors”, which enables researchers to better understand how human cells function and stay healthy. Researchers at the University of Stuttgart have further developed CRISPR for this purpose. They present their CRISPRgenee method in Cell Reports Methods.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-crispr-method-leads-better-understanding-cell-functions
  • Press release - 15/09/2025

    How HIV enters the genome – Researchers identify previously unknown mechanism

    Researchers at Heidelberg Uni Hospital have decoded a previously unknown mechanism by which HIV-1 selects its integration targets in the human genome. A research team identified RNA:DNA hybrids as molecular signposts for the virus. These findings reveal a vulnerability in the life cycle of HIV and provide therapeutic approaches for specifically controlling HIV reservoirs in the body. This has been one of the obstacles to curative HIV therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-hiv-enters-genome-researchers-identify-previously-unknown-mechanism
  • Press release - 12/09/2025

    In bad company: Immune cells in the tumor environment determine the success of therapy for childhood brain tumors

    The cellular environment of a tumor can either support or sabotage recovery. The most comprehensive study to date on the tumor microenvironment in low-grade gliomas, conducted by KiTZ, Jena University Hospital, the DKFZ, and Heidelberg University Hospital, shows what a supportive or obstructive “neighborhood” looks like in childhood brain tumors. The study also provides clues as to how tumor communication might be blocked.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/bad-company-immune-cells-tumor-environment-determine-success-therapy-childhood-brain-tumors
  • Press release - 09/09/2025

    Molecular Biomimetics: The Cell Nucleus as a Model for DNA-based Computer Chips

    In the human body, stem cells process genetic information in an exceptionally reliable and very fast manner. To do this, they access certain sections of the DNA in the cell nucleus. Researchers at KIT have investigated how the DNA-based information processing system works. Their results show that this process is comparable to processes in modern computers and could therefore serve as a model for new types of DNA-based computer chips.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-biomimetics-cell-nucleus-model-dna-based-computer-chips
  • Press release - 04/09/2025

    Rare bone tumors: Tailor-made mini-proteins switch off tumor drivers

    Chordomas are rare bone tumors for which there are no effective drugs. A research team from the DKFZ and the NCT Heidelberg has now developed a promising approach: Tailor-made mini-proteins specifically block the driver of tumor development. In the result, slowing the growth of chordoma cells in the laboratory and in a mouse model, while also revealing further molecular vulnerabilities of the tumor that could be addressed with approved drugs.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/rare-bone-tumors-tailor-made-mini-proteins-switch-tumor-drivers-1
  • Press release - 03/09/2025

    Therapeutic vaccination against HPV-related tumors: Nanoparticles make the difference

    Researchers from the German Cancer Research Center (DKFZ) have collaborated with the SILVACX project group at Heidelberg University to develop a therapeutic vaccination concept that can mobilize the immune system to target cancer cells. The team showed that virus peptides coupled to silica nanoparticles can elicit effective T-cell responses against HPV-related tumors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/therapeutic-vaccination-against-hpv-related-tumors-nanoparticles-make-difference
  • Press release - 28/08/2025

    Inhibition of cell division induces immunoreactive peptides in cancer cells

    A team of scientists from the German Cancer Research Center (DKFZ) and the Netherlands Cancer Institute has discovered a previously unknown vulnerability in cancer cells: When cell division is blocked with chemotherapeutic agents such as Taxol, cancer cells produce small immunogenic peptides that could open up new avenues for immune-based cancer therapies.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/inhibition-cell-division-induces-immunoreactive-peptides-cancer-cells
  • Press release - 21/08/2025

    Nanodroplets Could Speed Up the Search for New Medicine

    Until now, the early phase of drug discovery for the development of new therapeutics has been cost- and time-intensive. Researchers at KIT have developed a platform on which extremely miniaturized nanodroplets with a volume of 200 nanoliters per droplet and containing 300 cells per test can be arranged. This platform enables the researchers to synthesize and test thousands of therapeutic agents on the same chip, saving time and resources.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nanodroplets-could-speed-search-new-medicine
  • Press release - 14/08/2025

    Freezing brain tumor cells in a dormant state

    Every brain tumor is made up of cells in successive stages of activation. Researchers have now analyzed the individual structure of these activation pyramids in malignant brain tumors. In doing so, they discovered a signaling protein that slows down the transition from a dormant to an activated state by epigenetically reprogramming the cells. The hope is that this will permanently freeze cancer cells in a dormant state and thus halt tumor growth.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/freezing-brain-tumor-cells-dormant-state
  • Press release - 12/08/2025

    Biomarkers for Brain Insulin Resistance Discovered in the Blood

    If the brain no longer responds properly to insulin (insulin resistance), this can lead to overweight, diabetes, and Alzheimer's disease. Researchers at the DZD in Potsdam and Tübingen have discovered small chemical modifications to genetic material (epigenetic changes*) in the blood that indicate how well the brain responds to insulin. These markers could help to detect insulin resistance in the brain – by means of a simple blood test.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/biomarkers-brain-insulin-resistance-discovered-blood
  • Press release - 05/08/2025

    Playing Dominos: how an artificial protein emerges from fitting together individual components

    The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/playing-dominos-how-artificial-protein-emerges-fitting-together-individual-components
  • Press release - 04/08/2025

    FOXP1 syndrome: Potential therapeutic approach discovered for rare language development disorder

    FOXP1 syndrome is a congenital disorder in which the brain development of affected children is severely impaired due to a genetic variant. A research team from the Medical Faculty Heidelberg at Heidelberg University has now demonstrated in mice, that the inhibition of a specific enzyme in the brain can improve abnormal behavior and immune cell dysfunction in the brain. The results have been published in the journal Advanced Science.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/foxp1-syndrome-potential-therapeutic-approach-discovered-rare-language-development-disorder
  • Breath test replaces invasive diagnostics - 30/07/2025 Der Sensor auf einer Handfläche, der gerade einmal ein Drittel der des Handtellers bedeckt.

    Novel smartphone sensor offers innovative breath test to detect Helicobacter infection

    The stomach bacterium Helicobacter pylori is widespread and, if left undetected, can impact our well-being and also lead to serious health conditions. While effective treatments exist, a reliable diagnosis is essential. To address this, researchers have developed an affordable breath test that uses a mini-sensor to detect the presence of the bacterium. They are currently working on a smartphone-compatible version for self-testing.

    https://www.gesundheitsindustrie-bw.de/en/article/news/novel-smartphone-sensor-offers-innovative-breath-test-detect-helicobacter-infection
  • Press release - 29/07/2025

    New method to design custom protein binder

    Designing protein binders from scratch has long been a daunting challenge within the field of computational biology. Researchers have now developed an innovative, training-free pipeline that uses the fundamental principle of shape complementarity to design site-specific protein binders, which are then optimised to fit precisely onto chosen target sites. The researchers tested this on proteins linked to cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-method-design-custom-protein-binder
  • Press release - 24/07/2025

    The origin of evil: stem cell-like cells are the reason for relapses of blood cancer in children and adolescents

    Stem cell-like leukemia cells are responsible for relapses in children and adolescents with a certain type of blood cancer, T-ALL. Researchers at the Hopp Children's Cancer Center Heidelberg (KiTZ), the Molecular Medicine Partnership Unit and the German Cancer Research Center were able to show this in a study. The results could help to overcome resistance in this form of blood cancer and prevent relapses.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/origin-evil-stem-cell-cells-are-reason-relapses-blood-cancer-children-and-adolescents
  • Press release - 24/07/2025

    What makes cells migrate – and what can stop them

    Konstanz researchers identify an enzyme that plays a role in the migration of cells in our body - not only during normal tissue formation and wound healing, but also when tumor cells metastasize. This makes the enzyme an interesting candidate for potential future therapeutic approaches.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-makes-cells-migrate-and-what-can-stop-them
  • Press release - 22/07/2025

    Colorectal cancer in type 2 diabetes: An insightful look into the microenvironment of tumors

    Diabetics have a higher risk of colorectal cancer and often a poorer prognosis after developing the disease. The biological mechanisms behind this association were largely unknown. A research team at the German Cancer Research Center (DKFZ) has now discovered that tumors with a low number of immune cells appear to be particularly susceptible to the harmful effects of diabetes.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/colorectal-cancer-type-2-diabetes-insightful-look-microenvironment-tumors
  • Press release - 21/07/2025

    Cancer Cachexia: Liver Identified as Driver of Body Wasting

    Many people with cancer experience dramatic loss of muscle and fat tissue. In many cases, even the heart muscle is affected. This wasting syndrome, affects around half of all cancer patients. Researchers from Helmholtz Munich, in collaboration with Heidelberg University Hospital, the Technical University of Munich, and the German Center for Diabetes Research, have now identified a previously overlooked driver of cachexia: the liver.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-cachexia-liver-identified-driver-body-wasting
  • Press release - 15/07/2025

    Mapping the metabolism of blood stem cells

    Researchers from the Max Planck Institute of Immunobiology and Epigenetics in Freiburg and ETH Zürich have created the first integrated map detailing the metabolic and molecular changes in human blood stem cells as they age, specialize, or turn cancerous. Their innovative research, made possible by highly sensitive low-input techniques, identifies the nutrient choline, as a key player in preserving youthful stem cell traits.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/mapping-metabolism-blood-stem-cells

Page 1 / 5

sb_search.block.search_result.other.pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2026
Website address: https://www.gesundheitsindustrie-bw.de/en/search